Everyone can speculate but no one knows. At this juncture, what a collaborative company wants will almost certainly happen first and no one here knows what that company might want to do or even who they are. They might want to proceed with development of B and do Kevetrin at some point afterwards. They might want to proceed with Kevetrin first. They might want to do both and go full steam ahead. Probably would depend entirely on the makeup of the company. Agreement, partnership, buyout. Any of those would take this stock dramatically higher. That is why everyone here is here. No matter what many say.